drugset
drugset / Trial / NCT04986540

A Trial of SHR - 1906 in Healthy Subjects

NCT04986540 ↗

Phase 1 Completed 72 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a phase 1 single dose escalation study of SHR-1906 in healthy subjects. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1906 in healthy subjects.

Timeline

Start
2021-08-10
Primary completion
2022-09-07
Completion
2022-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1906 Unknown — Intravenous

Indications

idiopathic pulmonary fibrosis